Direxion Daily S&P Biotech Bear 3X ETF
LABD
18 hedge funds and large institutions have $41.8M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 4 closing their positions.
237% more call options, than puts
Call options by funds: $22.6M | Put options by funds: $6.7M
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
49.68% more ownership
Funds ownership: 38.98% → 88.66% (+50%)
40% more capital invested
Capital invested by funds: $29.9M → $41.8M (+$11.9M)
13% more funds holding
Funds holding: 16 → 18 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.03M |
| 2 |
VF
Virtu Financial
New York
|
+$4.09M |
| 3 |
HF
HRT Financial
New York
|
+$3.13M |
| 4 |
Jane Street
New York
|
+$3.11M |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$1.65M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$752K |
| 3 |
Goldman Sachs
New York
|
-$373K |
| 4 |
QT
Quantbot Technologies
New York
|
-$177K |
| 5 |
Citigroup
New York
|
-$19.5K |
LABD Hedge Fund Activity: Q3 2022 in Review
18 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q3 2022, worth a combined $41.8M — up 40% from $29.9M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new LABD positions and 4 closed out — a net gain of 2 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $9.03M. The largest seller was Squarepoint, exiting entirely with an estimated $1.65M sold.
- 18 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q3 2022, up from 16 in Q2 2022.
- Funds reported $41.8M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q3 2022, up 40% quarter-over-quarter.
- 6 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q3 2022 and 4 closed out, a net change of +2 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q3 2022 was Susquehanna International Group, an estimated $9.03M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q3 2022 was Squarepoint, an estimated $1.65M sold.
Based on aggregated 13F filings for Q3 2022.